Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prednisone-premedication R-CHOP vs standard R-CHOP in DLBCL to reduce rituximab infusion reactions
ChiCTR2300070327Phase 4Completed
- Sponsor
- Jiujiang University Affiliated Hospital
- Start
- Jan 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial of rituximab in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by Jiujiang University Affiliated Hospital. Primary endpoint: Incidence of rituximab-related infusion reactions. Started Jan 2019; status: completed.
02
Drugs
rituximab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on ChiCTR2300070327.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300070327.